Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
Delayed Nasdaq  -  04:00 2022-09-28 pm EDT
9.940 USD   +4.85%
09/28Alx Oncology : Corporate Presentation
PU
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
GL
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about ALX ONCOLOGY HOLDINGS INC.
09/28Alx Oncology : Corporate Presentation
PU
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
GL
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
AQ
09/01ALX Oncology Announces Upcoming Investor Conference Participation
GL
08/26UBS Adjusts ALX Oncology Price Target to $31 From $37, Maintains Buy Rating
MT
08/16ALX Oncology's Evorpacept Picked for New Treatment Arm in Breast Cancer Trial
MT
08/16ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of..
PR
08/15Alx Oncology : Corporate Presentation
PU
08/15ALX Oncology Says Evorpacept Selected in Early-Stage Trial in Combination With Enhertu ..
MT
08/15ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of..
GL
08/15ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative Announces the Sele..
CI
08/11First Patient Dosed in ALX Oncology's Mid-Stage Trial of Colorectal Cancer Combination ..
MT
08/11ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of E..
GL
08/11ALX Oncology Holdings Inc. Announces First Patient Dosed in Phase 2 Investigator-Sponso..
CI
08/09Cantor Fitzgerald Adjusts ALX Oncology Holdings' Price Target to $32 from $60, Maintain..
MT
08/09Credit Suisse Lowers ALX Oncology Holdings' PT to $38 from $43, Notes Increased Discoun..
MT
08/08Alx Oncology : Reports Second Quarter 2022 Financial Results and Provides Clinical Develop..
PU
08/08Alx Oncology : Corporate Presentation
PU
08/08ALX ONCOLOGY HOLDINGS INC Management's Discussion and Analysis of Financial Condition ..
AQ
08/08ALX Oncology Holdings Inc. Reports Earnings Results for the Second Quarter and Six Mont..
CI
08/08ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Develo..
GL
08/08ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Develo..
GL
08/01ALX Oncology Receives FDA Fast-Track Designation for Head, Neck Cancer Drug
MT
08/01ALX Oncology's Evorpacept Receives Fast Track Designation from FDA as First-Line Treatm..
GL
08/01ALX Oncology's Evorpacept Receives Fast Track Designation from FDA as First-Line Treatm..
GL
08/01ALX Oncology's Evorpacept Receives Fast Track Designation from FDA as First-Line Treatm..
CI
06/29ALX Oncology Secures FDA Orphan Drug Designation for Evorpacept
MT
06/29ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment..
GL
06/29ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment..
AQ
06/29ALX Oncology's Evorpacept Gets FDA Designation for Leukemia
DJ
06/24ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to R..
CI
06/24ALX Oncology Holdings Inc.(NasdaqGS:ALXO) dropped fr..
CI
06/24ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to R..
CI
06/24ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to R..
CI
06/24ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to R..
CI
06/24ALX Oncology Holdings Inc.(NasdaqGS:ALXO) dropped fr..
CI
06/24ALX Oncology Holdings Inc.(NasdaqGS:ALXO) dropped fr..
CI
06/24ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to R..
CI
06/24ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to R..
CI
06/24ALX Oncology Holdings Inc.(NasdaqGS:ALXO) dropped fr..
CI
06/24ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to R..
CI
06/24ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to R..
CI
06/24ALX Oncology Holdings Inc.(NasdaqGS:ALXO) dropped fr..
CI
06/21ALX Oncology Holdings Inc.(NasdaqGS:ALXO) dropped fr..
CI
06/16Alx Oncology Holdings Inc : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/07Alx Oncology : Corporate Presentation
PU
06/06Stifel Adjusts Price Target on ALX Oncology Holdings to $16 From $35, Reiterates Buy Ra..
MT
06/03ALX Oncology Announces Evorpacept Clinical Program Updates
GL
06/03ALX Oncology Announces Evorpacept Clinical Program Updates
GL
06/03ALX Oncology Holdings Inc Announces Evorpacept Clinical Program Updates
CI
06/01ALX Oncology to Participate in the Jefferies 2022 Healthcare Conference
GL
05/19Piper Sandler Adjusts Price Target on ALX Oncology Holdings to $48 From $70, Reiterates..
MT
05/09ALX ONCOLOGY HOLDINGS INC Management's Discussion and Analysis of Financial Condition ..
AQ
05/09ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Develop..
GL
05/09ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Develop..
AQ
05/09ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
04/12Alx Oncology : Appoints Itziar Canamasas, Ph.D., to its Board of Directors - Form 8-K
PU
04/12Alx Oncology Holdings Inc : Change in Directors or Principal Officers (form 8-K)
AQ
04/12ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors
GL
04/12ALX Oncology Appoints Itziar Canamasas, Ph.D., to Its Board of Directors
CI
03/28ALX Oncology Holdings Files $450 Million Mixed Shelf
MT
03/25Alx Oncology : Corporate Presentation
PU
03/14Cantor Fitzgerald Adjusts Price Target for ALX Oncology to $60 From $103, Maintains Ove..
MT
03/02ALX Oncology Doses First Patient in Phase 2/3 Trial of Evorpacept in Gastric, Gastroeso..
MT
03/02ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept..
GL
03/02ALX Oncology Holdings Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of E..
CI
03/01Stifel Adjusts ALX Oncology Holdings' Price Target to $36 from $60, Maintains Buy Ratin..
MT
03/01HC Wainwright Adjusts Price Target on ALX Oncology Holdings to $80 From $100, Reiterate..
MT
02/28ALX ONCOLOGY HOLDINGS INC Management's Discussion and Analysis of Financial Condition ..
AQ
02/28ALX Oncology Holdings Inc. Reports Earnings Results for the Full Year Ended December 31..
CI
02/28Alx Oncology : Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Cl..
PU
02/28ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides C..
AQ
02/28ALX Oncology Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended Decemb..
CI
02/14Credit Suisse Lowers ALX Oncology Holdings' Price Target to $41 from $53, Maintains Out..
MT
01/27ALX Oncology Gets FDA Orphan Drug Designation for Evorpacept
DJ
1  2  3  4Next
Upcoming event on ALX ONCOLOGY HOLDINGS INC.